1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Smoking Cessation - Pipeline Review, H1 2015

Smoking Cessation - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 102 pages

Smoking Cessation - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Smoking Cessation - Pipeline Review, H1 2015’, provides an overview of the Smoking Cessation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Smoking Cessation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Smoking Cessation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Smoking Cessation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Smoking Cessation - Pipeline Review, H1 2015
Table of Contents
Introduction 8
Global Markets Direct Report Coverage 8
Smoking Cessation Overview 9
Therapeutics Development 10
Pipeline Products for Smoking Cessation - Overview 10
Pipeline Products for Smoking Cessation - Comparative Analysis 11
Smoking Cessation - Therapeutics under Development by Companies 12
Smoking Cessation - Therapeutics under Investigation by Universities/Institutes 15
Smoking Cessation - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Smoking Cessation - Products under Development by Companies 19
Smoking Cessation - Products under Investigation by Universities/Institutes 20
Smoking Cessation - Companies Involved in Therapeutics Development 21
Aradigm Corporation 21
Arena Pharmaceuticals, Inc. 22
Astraea Therapeutics, LLC 23
Bioprojet SCR 24
Embera NeuroTherapeutics, Inc. 25
FORUM Pharmaceuticals Inc. 26
GlaxoSmithKline plc 27
Invion Limited 28
Johnson and Johnson 29
Marinus Pharmaceuticals, Inc. 30
NAL Pharmaceuticals Ltd. 31
Pfizer Inc. 32
Royalty Pharma 33
Selecta Biosciences, Inc. 34
Targacept, Inc. 35
Zynerba Pharmaceuticals, Inc. 36
Smoking Cessation - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
(oxazepam + metyrapone) - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Anatabine - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
ARD-1600 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
BP-1.4979 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
encenicline hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
ganaxolone - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
GSK-598809 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
lorcaserin hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
nadolol - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
NIC7-DT - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
nicotine - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
nicotine - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Nicotine Vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
PF-05402536 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
PF-06413367 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
SEL-068 - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
Small Molecule for Smoking Cessation - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
Small Molecule for Smoking Cessation and Appetite Suppression - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
Smoking Cessation - Recent Pipeline Updates 78
Smoking Cessation - Dormant Projects 90
Smoking Cessation - Discontinued Products 91
Smoking Cessation - Product Development Milestones 92
Featured News and Press Releases 92
Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation 92
Nov 04, 2014: Lorcaserin Meets Primary Endpoint And Confirms Proof-Of-Concept As Potential Aid For Smoking Cessation In Investigational Phase II Clinical Study 93
Nov 03, 2014: Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation 94
Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform 95
May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ (lorcaserin HCl) CIV by 50% 96
Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial 96
Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 97
Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs 98
Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint 99
Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation 99
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102

List of Tables

Number of Products under Development for Smoking Cessation, H1 2015 10
Number of Products under Development for Smoking Cessation - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Investigation by Universities/Institutes, H1 2015 20
Smoking Cessation - Pipeline by Aradigm Corporation, H1 2015 21
Smoking Cessation - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 22
Smoking Cessation - Pipeline by Astraea Therapeutics, LLC, H1 2015 23
Smoking Cessation - Pipeline by Bioprojet SCR, H1 2015 24
Smoking Cessation - Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 25
Smoking Cessation - Pipeline by FORUM Pharmaceuticals Inc., H1 2015 26
Smoking Cessation - Pipeline by GlaxoSmithKline plc, H1 2015 27
Smoking Cessation - Pipeline by Invion Limited, H1 2015 28
Smoking Cessation - Pipeline by Johnson and Johnson, H1 2015 29
Smoking Cessation - Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 30
Smoking Cessation - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 31
Smoking Cessation - Pipeline by Pfizer Inc., H1 2015 32
Smoking Cessation - Pipeline by Royalty Pharma, H1 2015 33
Smoking Cessation - Pipeline by Selecta Biosciences, Inc., H1 2015 34
Smoking Cessation - Pipeline by Targacept, Inc., H1 2015 35
Smoking Cessation - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 36
Assessment by Monotherapy Products, H1 2015 37
Assessment by Combination Products, H1 2015 38
Number of Products by Stage and Target, H1 2015 40
Number of Products by Stage and Mechanism of Action, H1 2015 42
Number of Products by Stage and Route of Administration, H1 2015 44
Number of Products by Stage and Molecule Type, H1 2015 46
Smoking Cessation Therapeutics - Recent Pipeline Updates, H1 2015 78
Smoking Cessation - Dormant Projects, H1 2015 90
Smoking Cessation - Discontinued Products, H1 2015 91

List of Figures

Number of Products under Development for Smoking Cessation, H1 2015 10
Number of Products under Development for Smoking Cessation - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Products, H1 2015 17
Assessment by Monotherapy Products, H1 2015 37
Number of Products by Top 10 Targets, H1 2015 39
Number of Products by Stage and Top 10 Targets, H1 2015 39
Number of Products by Top 10 Mechanism of Actions, H1 2015 41
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 41
Number of Products by Top 10 Routes of Administration, H1 2015 43
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 43
Number of Products by Top 10 Molecule Types, H1 2015 45
Number of Products by Stage and Top 10 Molecule Types, H1 2015 45

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.